Pyrrolizidine alkaloids, a group of natural products produced by numerous plant families, are an interesting class of molecules due to their potent biological activities and diverse chemical structures.^[@ref1]^ More than 650 pyrrolizidine alkaloids have been isolated from over 6000 plants,^[@ref2]^ and many of them have been demonstrated to be hepatotoxic, genotoxic, and mutagenic.^[@ref3]^ Secondary metabolites from microbes possessing the pyrrolizidine nucleus, such as pyrrolams,^[@ref4]^ jenamidines,^[@ref5]^ and bohemamines,^[@ref6]^ have also been identified. These structures have attracted the attention of synthetic chemists,^[@ref7]^ especially bohemamines, which represented a rare pyrrolizidine subclass due to the methylation pattern and presence of the amide nitrogen on the pyrrolizidine skeleton. To date, only five bohemamine-type pyrrolizidine alkaloids, bohemamine (**12**), bohemamines B (**13**) and C (**14**), 5-chlorobohemamine C (**15**), and NP25302 (**9**), have been reported.^[@ref6]^

As part of our studies to search for unusual structural features from marine-derived actinomycetes for further investigation, our attention was drawn to a series of metabolites contained in the extract of *Streptomyces spinoverrucosus* strain SNB-048. These compounds showed UV absorptions similar to those of bohemamines in an LC-UV-MS analysis.^[@ref6]^ Chemical investigation on this strain has resulted in the isolation of two novel bohemamine-type pyrrolizidine alkaloids, spithioneines A and B (**10** and **11**), which possess an unusual ergothioneine moiety.^[@ref8]^ Herein, we report another six new bohemamine analogues, bohemamines D--I (**3**--**8**), and two new 1,3-oxazin-6-one derivatives, spinoxazines A and B (**1** and **2**), together with a known bohemamine analogue, NP25302 (**9**). Structurally, compounds **1** and **2** possess a 1,3-oxazin-6-one system, which is rare in natural products.^[@ref21]^
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Results and Discussion {#sec2}
======================

Spinoxazine A (**1**) was obtained as a white powder. The molecular formula was determined as C~13~H~16~N~2~O~4~ according to its HRESIMS peak at *m*/*z* 265.1183 \[M + H\]^+^. There were multiple IR stretches at 1740 cm^--1^ indicative of a lactam or ester moiety (five-membered-ring lactams absorb in the 1750--1700 cm^--1^ region; four-membered-ring lactams absorb at 1760--1730 cm^--1^; esters absorb at 1750--1735 cm^--1^; α,β-unsaturated esters appears at 1730--1715 cm^--1^). The ^13^C NMR spectrum showed 13 carbon signals that were classified by HSQC as three methyl carbons, one sp^3^ methylene carbon, four methine groups (two olefinic carbons, one carbon connected with oxygen, and one carbon connected with nitrogen), and five nonprotonated carbons (three carbonyls and two olefinic carbons) ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). The ^1^H NMR spectrum showed five coupled signals at δ~H~ 1.23 (H-8, d, *J* = 6.5), 4.55 (H-4, qd, *J* = 6.7, 6.6), 4.43 (H-5, ddd, *J* = 8.8, 8.0, 6.7), 2.67 (H-6β, dd, *J* = 16.9, 8.0), and 2.63 (H-6α, dd, *J* = 16.9, 8.8). These data combined with COSY correlations of H-8/H-4/H-5/H-6 and the key HMBC correlations of H-8 to C-4/C-5 and H-4/H-5 to C-6/C-7 ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) constituted the 4-hydroxy-5-methyl-γ-lactam moiety. Two vinyl methyl groups at δ~H~ 2.25 (H-5′, d, *J* = 1.2 Hz) and 2.03 (H-4′, d, *J* = 1.2 Hz) and one olefinic proton signal at δ~H~ 5.98 (m), along with the HMBC correlations of H-2′ to C-4′/C-5′ and H-4′ to C-5′ ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}), indicated the presence of an isobutenyl fragment. The isobutenyl fragment should be connected with C-1′ (δ~C~ 163.7), which was determined by the HMBC correlation of H-2′ to C-1′ ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). The remaining ^1^H and ^13^C NMR signals and the HMBC correlations of H-2 (δ~H/C~ 6.73/89.0) to C-1 (δ~C~ 159.8) and C-3 (δ~C~ 155.3) ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}), along with the molecular formula, provided two possible structures that could not be easily distinguished: a 1,3-oxazin-6-one (**1**) or an unsaturated β-lactam unit (**1a**) ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). The proposed unsaturated β-lactam in **1a** would be unprecedented in a natural product. Only one natural product possessing an unsaturated β-lactam moiety was reported,^[@ref9]^ but it was later revised to be a six-membered-ring metabolite.^[@ref10]^ Synthetic efforts to produce similar unsaturated β-lactams have been reported; however, literature reports suggest that such β-lactams rearrange to form the corresponding 1,3-oxazin-6-ones ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).^[@ref11]^ In general, the ^1^H and ^13^C NMR data for the corresponding β-lactam and 1,3-oxazin-6-one structures for this natural product would be nearly identical. Predicted ^13^C NMR shifts of both 1,3-oxazin-6-one (**1**) and β-lactam (**1a**), which were computed at the B3LYP/6-311++G(2d,p)//B3LYP/6-31G(d) level (full details on the calculation can be found in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jnatprod.5b00604/suppl_file/np5b00604_si_001.pdf)),^[@ref12]^ strongly support that the chemical shift values of **1** are consistent with a 1,3-oxazin-6-one skeleton ([Table S1](http://pubs.acs.org/doi/suppl/10.1021/acs.jnatprod.5b00604/suppl_file/np5b00604_si_001.pdf)), particularly the ^13^C shifts of C-1, C-2, and C-3. The linkage between the γ-lactam and the 1,3-oxazin-6-one could be confirmed by the HMBC correlation of H-4 to C-3.

![Mechanism for the Conversion of *N*-Acyl-β-lactams into 1,3-Oxazin-6-ones](np-2015-006049_0010){#sch1}

![Key correlations for the structural assignment of **1**--**8**.](np-2015-006049_0003){#fig1}

![Two structures, **1** and **1a**, in general agreement with the NMR data.](np-2015-006049_0004){#fig2}

###### ^1^H (600 MHz) and ^13^C (100 MHz) NMR Data for Compounds **1** and **2** in DMSO-*d*~6~

       **1**         **2**                                     
  ---- ------------- --------------------------- ------------- ---------------------
  1    159.8, C                                  159.9, C       
  2    89.0, CH      6.73, s                     88.3, CH      6.79, s
  3    155.3, C                                  155.5, C       
  4    57.7, CH      4.55, qd (6.7, 6.6)         54.3, CH      4.65, qd (6.9, 6.6)
  5    64.1, CH      4.43, ddd (8.8, 8.0, 6.7)   24.7, CH~2~   2.21, m; 1.71, m
  6    39.3, CH~2~   2.67, dd (16.9, 8.0);       31.4, CH~2~   2.84, m; 2.45, m
                     2.63, dd (16.9, 8.8)                       
  7    173.4, C                                  176.0, C       
  8    13.3, CH~3~   1.23, d (6.5)               20.0, CH~3~   1.31, d (6.4)
  1′   163.7, C                                  163.7, C       
  2′   116.2, CH     5.98, m                     116.2, CH     5.98, m
  3′   158.7, C                                  158.7, C       
  4′   28.0, CH~3~   2.03, d (1.2)               28.1, CH~3~   2.03, s
  5′   21.0, CH~3~   2.25, d (1.2)               21.1, CH~3~   2.25, s

NOE correlations between H-8 and H-5/H-6β, between H-4 and H-5, and between H-5 and H-6α/H-6β were observed in the 2D NOESY spectrum, suggesting the relative configuration of **1** as shown ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). NOE correlations combined with the coupling constants between H-4 and H-5 (*J* = 6.7 Hz), between H-5 and H-6α (*J* = 8.8 Hz), and between H-5 and H-6β (*J* = 8.0 Hz) also indicated the conformation of **1** as shown in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}. We utilized the empirical electronic circular dichrosim (ECD) rule of γ-lactams^[@ref13]^ to determine the absolute configuration of **1**. The ECD sign of γ-lactams can be determined by addition of two effects: configuration of C~α~ and ring chirality. If the γ-lactams have no lone pair electrons on the C~α~ substituent, the ECD signs are determined by the ring chirality (conformation A gives a negative sign, and B gives a positive sign) ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}).^[@ref13]^ The conformation of (4*S*, 5*S*)-**1**, suggested by NOE correlations and chemical calculation ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jnatprod.5b00604/suppl_file/np5b00604_si_001.pdf)), is consistent with A, which was responsible for the negative Cotton effect (π--π\* transition) in accordance with the measured negative ECD Cotton effect at λ~max~ 254 nm of **1** ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). As the 1,3-oxazin-6-one group connected with the nitrogen nearly lay on the same plane of the amide, it made a very small contribution to the lactam Cotton effect. Moreover, the predicted ECD spectrum was obtained by the TDDFT \[B3LYP/6-31G(d)\] method ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jnatprod.5b00604/suppl_file/np5b00604_si_001.pdf)),^[@ref14]^ which was subsequently compared with the experimental data. The measured ECD curve of **1** showed a Cotton effect at λ~max~ (Δε) 254 (−4.7) nm, matching with the calculated ECD curve of (4*S*,5*S*)-**1** ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}).

![Selected NOESY correlations of **1**, **3a**, and **4**--**8**.](np-2015-006049_0005){#fig3}

![(a) ECD spectra of **1** and **2**. (b) Ring chirality and ECD sign of γ-lactams and the conformation of **1**.](np-2015-006049_0006){#fig4}

![Measured and calculated ECD spectra for **1**.](np-2015-006049_0007){#fig5}

The molecular formula of spinoxazine B (**2**) was assigned as C~13~H~16~N~2~O~3~ based on the HRESIMS, which was only one oxygen less than that of **1**. Careful comparison of its ^1^H and ^13^C NMR spectra ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}) with those of **1** showed that methylene signals at δ~C/H~ 24.7/2.21 and 1.71 in **2** replaced the corresponding oxygenated methine signals at δ~C/H~ 64.1/4.43 in **1**. The COSY correlations of H-8/H-4/H-5/H-6 and the key HMBC correlations of H-8 to C-4/C-5 and H-4/H-5 to C-6/C-7 also supported this change in **2** ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). The ECD Cotton effect at λ~max~ (Δε) 267 (−2.6) was nearly identical to **1** ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}), indicating the same absolute configuration.

Bohemamine D (**3**) was isolated as a colorless oil. Its molecular formula was C~13~H~18~N~2~O~3~ based on the HRESIMS data. The UV spectrum showed similar absorptions to bohemamines at 252, 283, and 332 nm.^[@ref6]^ Comparison of its NMR spectra with those of known bohemamine analogues indicated that the ^1^H and ^13^C NMR data of **3** ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}) were similar to NP25302 (**9**).^[@cit6c]^ The signal of the C-7 methyl group in NP25302 was no longer present, and δ~C~ at C-7 was shifted deshielded to 95.3, leading to the assignment of a C-7 hydroxy group. The molecular formula and the key HMBC correlations of H-8 to C-4/C-5 and H-6 to C-4/C-5/C-7/C-1 ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) also confirmed the structure of **3**. In order to determine its relative configuration, a methylation reaction was carried out using iodomethane and sodium hydride to generate **3a** ([Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acs.jnatprod.5b00604/suppl_file/np5b00604_si_001.pdf)). In the NOESY spectrum of compound **3a**, the signal between H-8 and 7-OCH~3~ could be observed, which indicated the relative configuration of **3** as shown. The octant rule for cyclopentenone^[@ref8],[@ref15]^ was used to determine the absolute configuration ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}). The conformation of (4*S*,7*S*)-**3** as shown in [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"} was placed in accordance with the octant rule model. The functional group at C-7 lying in the back lower left area was responsible for the negative Cotton effect (n−π\*), which was consistent with the Cotton effect at 335 nm (Δε −19.0). Moreover, the ECD helicity rule of α,β-unsaturated ketones^[@ref16]^ was used to further confirm the absolute configuration of compound **3**. The *P*-helicity of the O=C--C~α~=C~β~ torsion angle correlates the positive Cotton effect (π--π\*) at 297 nm ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}).

![ECD spectra and the representation of the octant rule and helicity rule for the cyclopentenone moiety of **3** (a) and **9** (b).](np-2015-006049_0008){#fig6}

###### ^1^H (600 MHz) and ^13^C (100 MHz) NMR Data for Compounds **3**--**5** in DMSO-*d*~6~

       **3**         **4**                 **5**                                             
  ---- ------------- --------------------- ------------- --------------------- ------------- ---------------------------
  1    198.9, C                            201.5, C                            203.2, C       
  2    89.1, CH      5.42, s               93.5, CH      5.41, s               93.1, CH      5.58, s
  3    168.4, C                            166.7, C                            168.0, C       
  4    55.2, CH      3.71, qd (6.7, 3.7)   62.9, CH      3.76, qd (6.9, 3.3)   62.0, CH      4.40, ddd (6.7, 2.2, 1.4)
  5    32.7, CH~2~   1.91, m; 1.74, m      87.0, CH      3.92, brs             128.0, CH     5.74, dd (6.0, 2.2)
  6    32.0, CH~2~   1.82, m; 1.71, m      77.3, CH      3.70, brs             133.9, CH     5.67, dd (6.0, 1.4)
  7    95.3, C                             78.4, C                             80.2, C        
  8    22.0, CH~3~   1.30, d (6.6)         23.2, CH~3~   1.31, s               24.8, CH~3~   1.22, s
  9                                        16.4, CH~3~   1.20, d (6.9)         17.9, CH~3~   1.19, d (6.6)
  1′   164.7, C                            163.9, C                            164.0, C       
  2′   117.9, CH     6.13, m               117.7, CH     5.99, m               117.5, CH     5.98, m
  3′   156.5, C                            156.0, C                            156.6, C       
  4′   27.3, CH~3~   1.90, d (1.2)         27.3, CH~3~   1.89, d (1.3)         27.3, CH~3~   1.90, d (1.2)
  5′   20.1, CH~3~   2.13, d (1.2)         20.0, CH~3~   2.14, d (1.3)         20.0, CH~3~   2.15, d (1.2)
  NH                 9.90, s                             10.31, s                            10.49, s

Bohemamine E (**4**) was also thought to be an analogue of bohemamines due to the similar UV absorptions at 252, 280, and 335 nm.^[@ref6]^ The molecular formula was determined as C~14~H~20~N~2~O~4~ by HRESIMS, with a H~2~O unit more than bohemamine (**12**). The 1D NMR spectrum was similar to **12** except for the shifts of C-5 and C-6. So, we deduced that the epoxide ring in **12** was hydrolyzed to yield compound **4**. COSY and HMBC data ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) confirmed this diol structure. NOE correlations between H-5 and H-9, between H-4 and H-8, and between H-6 and H-8 were observed in the 2D NOESY, suggesting the relative configuration of **4** as shown ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}).

The molecular formula of bohemamine F (**5**) was determined to be C~14~H~18~N~2~O~2~ from the protonated molecule peak at *m*/*z* 247.1441 \[M + H\]^+^ in the positive-ion HRESIMS spectrum, which was two hydrogen atoms less than that of NP25302 (**9**). Comparison of its ^1^H and ^13^C NMR spectra ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}) with those of **9** revealed that the signals of two methylene groups (C-5 and C-6) were replaced by two coupled olefinic methine signals (C-5: δ~C/H~ 128.0/5.74, dd, *J* = 6.0, 2.2; C-6: δ~C/H~ 133.9/5.67, dd, *J* = 6.0, 1.4). This structure can be confirmed by COSY correlations of H-9/H-4/H-5/H-6 and the key HMBC correlations from H-9 to C-4/C-5, H-6 to C-4/C-5/C-7/C-1, and H-8 to C-6/C-7. The relative configurations of C-4 and C-7 could be determined by the NOE correlation between H-8 and H-4.

The molecular formulas of bohemamines G--I (**6**--**8**) were determined as C~15~H~22~N~2~O~2~, C~14~H~20~N~2~O~2~, and C~16~H~18~N~2~O~2~ based on their HRESIMS spectra at *m*/*z* 263.1754 \[M + H\]^+^, 249.1596 \[M + H\]^+^, and 271.1443 \[M + H\]^+^, respectively. Examination of their ^1^H and ^13^C NMR spectra ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}) showed that they had the same pyrrolizidine skeleton as **9**, with variation only in the amide moiety. For compound **6**, the COSY correlations of H-2′/H-3′/H-4′ and H-5′/H-4′/H-6′ and the key HMBC correlations from H-2′ to C-1′, H-3′ to C-1′/C-4′, H-4′ to C-6′, H-5′ to C-6′, and H-6′ to C-3′ suggested the presence of a 4-methylpent-2-enamide side chain ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). The large coupling constant between H-2′ and H-3′ (*J* = 15.5 Hz) indicated the *E*- configuration. Compound **7** was determined to be an isomer of **9** ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}), where the amide moiety is a 2-methylbut-2-enamide group. This structure was supported by the COSY correlation of H-3′/H-4′ and the HMBC correlations from H-3′ to C-1′/C-5′, H-4′ to C-2′/C-3′, and H-5′ to C-1′ ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). The *E*-configuration for this side chain was determined by the NOE correlation between H-3′ and 3-NH ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). The NMR data were also consistent with those reported in the literature.^[@cit7b]^ In the 1D NMR spectrum of compound **8** ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}), the signals of a monosubstituted phenyl group were observed, which were further supported by 2D correlations ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). The NOE correlations between H-9 and H-5′β/H-6′β and between H-8′ and H-4′/H-5′α/H-6′α could be observed in the 2D NOESY spectra of compounds **6**--**8**, which revealed that they had the same relative configuration as shown ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}).

###### ^1^H (600 MHz) and ^13^C (100 MHz) NMR Data for Compounds **6**--**8** in DMSO-*d*~6~

       **6**         **7**                   **8**                                               
  ---- ------------- ----------------------- ------------- ----------------------- ------------- -----------------------
  1    204.0, C                              203.8, C                              203.9, C       
  2    93.5, CH      5.54, s                 93.3, CH      5.46, s                 93.9, CH      5.60, s
  3    166.3, C                              166.9, C                              167.1, C       
  4    54.2, CH      3.97, qd (6.6, 6.6)     54.3, CH      4.03, qd (6.6, 6.6)     54.4, CH      4.10, qd (6.6, 6.6)
  5    34.5, CH~2~   2.39, m; 1.74, m        34.4, CH~2~   2.37, m; 1.71, m        34.5, CH~2~   2.41, m; 1.75, m
  6    27.6, CH~2~   1.67, dd (12.5, 6.2);   27.7, CH~2~   1.67, dd (12.4, 6.3);   27.8, CH~2~   1.71, dd (12.3, 6.2);
                     1.52, dd (12.1, 6.2)                  1.53, dd (12.2, 6.5)                  1.56, dd (12.0, 6.9)
  7    73.1, C                               73.3, C                               73.4, C        
  8    24.7, CH~3~   1.15, s                 24.6, CH~3~   1.16, s                 24.6, CH~3~   1.20, s
  9    16.7, CH~3~   1.00, d (6.4)           16.8, CH~3~   1.01, d (6.5)           16.9, CH~3~   1.09, d (6.4)
  1′   163.7, C                              167.5, C                              165.8, C       
  2′   120.3, CH     6.19, dd (15.5, 1.5)    131.5, C                              133.4, C       
  3′   154.3, CH     6.91, dd (15.5, 6.3)    133.9, CH     6.50, qd (6.8, 1.4)     128.2, CH     7.91, d (7.5)
  4′   30.3, CH      2.50, m                 14.1, CH~3~   1.79, d (6.8)           128.5, CH     7.55, t (7.6)
  5′   21.1, CH~3~   1.04, d (6.8)           12.3, CH~3~   1.80, s                 132.5, CH     7.64, t (7.4)
  6′   21.1, CH~3~   1.04, d (6.8)                         10.28, s                128.5, CH     7.55, t (7.6)
  7′                                                                               128.2, CH     7.91, d (7.5)
  NH                 10.49, s                                                                    10.92, s

The absolute configuration of compound **9** has been determined as (4*S*,7*S*) by total synthesis,^[@cit5c]^ which can be confirmed with the octant rule for cyclopentenone ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}).^[@ref8],[@ref15]^ The ECD helicity rule of α,β-unsaturated ketones can also be used to confirm this conclusion. *M*-Helicity of the O=C--C~α~=C~β~ torsion angle of compound **9** was consistent with the negative Cotton effect (π--π\*) at 283 nm ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}), which suggested the absolute configuration of **9** as (4*S*,7*S*). The ECD spectra of compounds **4**--**8** showed the same Cotton effects as those of **9** ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}), indicating the same core configurations.

![ECD spectra of **4**--**8**.](np-2015-006049_0009){#fig7}

A plausible biogenetic pathway for spinoxazines A and B (**1** and **2**) and bohemamine D (**3**) is postulated ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). [l]{.smallcaps}-Glutamine undergoes decarboxylation and oxidation to generate the primary amine intermediate **a**, followed by condensation with two acetyl-CoA units and reduction to yield intermediate **b**.^[@ref17]^ Dual nucleophilic addition of the amine to the amide and methyl ketone carbonyls, respectively, followed by elimination and reduction would provide the pyrrolizidine core **d**. Oxidation of the bridgehead carbon would result in the hemiaminal intermediate **e**, which undergoes N-acylation to yield compound **3**.^[@ref8],[@ref18]^ Dehydrogenation of the pyrrolizidine core would give the ring cleavage intermediate **f**,^[@ref19]^ which could undergo a pericyclic reaction to form the 1,3-oxazin-6-one compound spinoxazine B (**2**). Further oxidation would generate spinoxazine A (**1**).

![Plausible Biogenetic Pathway of Compounds **1**--**3**](np-2015-006049_0011){#sch2}

Compounds **1**--**8** did not show cytotoxicity to non-small-cell lung cancer cell lines HCC366, A549, HCC44, and HCC1171. In addition, they showed no antibacterial activities against *Pseudomonas aeruginosa* and *Bacillus subtilis*.

Experimental Section {#sec3}
====================

General Experimental Procedures {#sec3.1}
-------------------------------

Optical rotations were recorded with an AUTOPOL AP IV-6W polarimeter equipped with a halogen lamp (589 nm). UV spectra were recorded on a Shimadzu UV-1601 UV--vis spectrophotometer. ECD spectra were measured on a JASCO J-815 spectrometer. IR spectra were obtained on a PerkinElmer Spectrum 1000 FT-IR spectrometer. ^1^H and 2D NMR spectroscopic data were recorded at 600 MHz in DMSO-*d*~6~ or CDCl~3~ solution on a Varian System spectrometer, and chemical shifts were referenced to the corresponding residual solvent signal (δ~H/C~ 2.50/39.52 for DMSO-*d*~6~ and δ~H/C~ 7.26/77.16 for CDCl~3~). ^13^C NMR spectra were acquired at 100 MHz on a Varian System spectrometer. High-resolution ESI-TOF mass spectra were provided by The Scripps Research Institute (La Jolla, CA, USA). Low-resolution LC/ESIMS data were measured using an Agilent 1200 series LC/MS system with a reversed-phase C~18~ column (Phenomenex Luna, 150 mm × 4.6 mm, 5 μm) at a flow rate of 0.7 mL/min. Preparative HPLC was performed on an Agilent 1200 series instrument with a DAD detector, using a reversed-phase C~18~ column (Phenomenex Luna, 250 × 10.0 mm, 5 μm), a phenyl-hexyl column (Phenomenex Luna, 250 × 10.0 mm, 5 μm), or a CN column (Phenomenex Luna, 250 × 10.0 mm, 5 μm). Sephadex LH-20 (GE Healthcare) and ODS (50 mm, Merck) were used for column chromatography. Artificial seawater was used in microbial fermentations as described in a previous reference.^[@ref20]^

Collection and Phylogenetic Analysis of Strain SNB-048 {#sec3.2}
------------------------------------------------------

*Streptomyces* sp. strain SNB-048 was isolated from a sand sample collected from a Bahamian tidal flat. The sediment was desiccated and stamped onto agar plates using gauze 1 acidic media (10 g starch, 1 g NaNO~3~, 0.5 g K~2~HPO~4~, 0.5 g MgSO~4~, 0.5 g NaCl, 0.01 g FeSO~4~, 1 L seawater, 15 g agar, pH adjusted to 5.3 with phosphate buffer). Bacterial colonies were selected and streaked to purity using the same agar media. Analysis of the strain by 16S rRNA revealed 99.9% identity to *Streptomyces spinoverrucosus*. The sequence is deposited in GenBank under accession no. KR091963.

Cultivation and Extraction of SNB-048 {#sec3.3}
-------------------------------------

Bacterium SNB-048 was cultured in 20 × 2.8 L Fernbach flasks each containing 1 L of a seawater-based medium (10 g starch, 4 g yeast extract, 2 g peptone, 1 g CaCO~3~, 40 mg Fe~2~(SO~4~)~3~·4H~2~O, 100 mg KBr) and shaken at 200 rpm at 27 °C. After 7 days of cultivation, sterilized XAD-7-HP resin (20 g/L) was added to adsorb the organic products, and the culture and resin were shaken at 200 rpm for 2 h. The resin was filtered through cheesecloth, washed with deionized H~2~O, and eluted with acetone. The acetone-soluble fraction was dried *in vacuo* to yield 1.2 g of extract. In order to get more material, another cultivation of 10 L was done under the same condition. From this cultivation, 460 mg of extract was obtained.

Purification {#sec3.4}
------------

The extract (1.2 g) of the first cultivation was fractionated by flash column chromatography on ODS (50 μm, 30 g), eluting with a step gradient of MeOH and H~2~O (10:90--100:0), and 12 fractions (Fr1.1--Fr1.12) were collected. Fractions 7 and 8 (403.7 mg) were combined and separated into six fractions (Fr1.7.1--Fr1.7.6) on Sephadex LH-20, eluting with MeOH. Fr1.7.3 (151.2 mg) was further separated into 16 fractions (Fr1.7.3.1--Fr1.7.3.16) by flash column chromatography on ODS (50 μm, 30 g), eluting with a step gradient of MeOH and H~2~O (10:90--100:0). Fr1.7.3.6 (6.3 mg) was purified by HPLC on a phenyl-hexyl column (Phenomenex Luna, 250 × 10.0 mm, 5 μm, 2.5 mL/min) using a gradient solvent system from 20% to 100% CH~3~CN (0.1% formic acid) over 20 min to yield compound **4** (1.4 mg, *t*~R~ = 9.5 min). Fr.7.3.8 (17.5 mg) was purified by HPLC on a phenyl-hexyl column (Phenomenex Luna, 250 × 10.0 mm, 5 μm, 2.5 mL/min) using a gradient solvent system from 20% to 85% CH~3~CN (0.1% formic acid) over 20 min to afford compound **3** (1.9 mg, *t*~R~ = 11.1 min). Fr1.7.3.9 (8.1 mg) was also separated by HPLC on a phenyl-hexyl column (Phenomenex Luna, 250 × 10.0 mm, 5 μm, 2.5 mL/min) using a gradient solvent system from 20% to 85% CH~3~CN (0.1% formic acid) over 20 min to afford compound **7** (0.9 mg, *t*~R~ = 12.5 min). Fr1.7.3.10 (31.7 mg) was separated by a reversed-phase HPLC (Phenomenex Luna, C~18~, 250 × 10.0 mm, 5 μm, 2.5 mL/min) using a gradient solvent system from 20% to 80% CH~3~CN (0.1% formic acid) over 20 min to yield compound **9** (3.8 mg, *t*~R~ = 13.4 min) and Fr1.7.3.10.4 (12.6 mg, *t*~R~ = 14.3 min). Fr1.7.3.10.4 (12.6 mg) was further purified by HPLC on a CN column (Phenomenex Luna, 250 × 10.0 mm, 5 μm, 2.5 mL/min) using a gradient solvent system from 20% to 100% CH~3~CN (0.1% formic acid) over 20 min to afford compounds **5** (3.3 mg, *t*~R~ = 11.5 min) and **8** (2.3 mg, *t*~R~ = 12.0 min). Fr1.7.3.11 (9.1 mg) was purified by HPLC on a phenyl-hexyl column (Phenomenex Luna, 250 × 10.0 mm, 5 μm, 2.5 mL/min) using a gradient solvent system from 20% to 100% CH~3~CN (0.1% formic acid) over 20 min to afford compound **6** (1.8 mg, *t*~R~ = 13.6 min). Fr1.7.5 (21.7 mg) was purified by reversed-phase HPLC (Phenomenex Luna, C~18~, 250 × 10.0 mm, 5 μm, 2.5 mL/min) using a gradient solvent system from 20% to 90% CH~3~CN (0.1% formic acid) over 15 min to afford Fr1.7.5.1 (1.2 mg, *t*~R~ = 12.2 min). Fr1.7.5.1 (1.2 mg) was further purified by HPLC on a phenyl-hexyl column (Phenomenex Luna, 250 × 10.0 mm, 5 μm, 2.5 mL/min) using a gradient solvent system from 20% to 100% CH~3~CN (0.1% formic acid) over 20 min to yield compound **1** (0.8 mg, *t*~R~ = 13.4 min). The extract (460 mg) of the second cultivation was fractionated by flash column chromatography on ODS (50 μm, 30 g), eluting with a step gradient of MeOH and H~2~O (10:90--100:0), and eight fractions (Fr2.1--Fr2.8) were collected. Fr2.4 (21.1 mg) separated into nine fractions (Fr2.4.1--Fr2.4.9) on Sephadex LH-20, eluting with MeOH. Fr2.4.6 (3.5 mg) was purified by reversed-phase HPLC (Phenomenex Luna, C~18~, 250 × 10.0 mm, 5 μm, 2.5 mL/min) using a gradient solvent system from 30% to 100% CH~3~CN (0.1% formic acid) over 20 min to yield compound **2** (0.6 mg, *t*~R~ = 15.7 min).

### Spinoxazine A (**1**): {#sec3.4.1}

white powder, \[α\]^23^~D~ +17 (*c* 0.05, MeOH); UV (MeOH) λ~max~ (log ε) 254 (4.04), 318 (3.79) nm; ECD (*c* = 0.87 mM, MeOH) λ~max~ (Δε) 291 (+0.5), 254 (−4.7) nm; IR (NaCl disk) ν~max~ 3398, 2982, 2925, 1740, 1594, 1541, 1394, 1272, 1258, 1208, 1187, 1102, 1071, 830 cm^--1^; ^1^H and ^13^C NMR, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}; HRESIMS *m*/*z* 265.1183 \[M + H\]^+^ (calcd for C~13~H~17~N~2~O~4~, 265.1183).

### Spinoxazine B (**2**): {#sec3.4.2}

white powder, \[α\]^23^~D~ +6 (*c* 0.03, MeOH); UV (MeOH) λ~max~ (log ε) 255 (4.10), 320 (3.82) nm; ECD (*c* = 1.33 mM, MeOH) λ~max~ (Δε) 333 (+0.5), 267 (−2.6) nm; IR (NaCl disk) ν~max~ 2918, 2850, 1739, 1734, 1593, 1540, 1387, 1254, 1184, 830 cm^--1^; ^1^H and ^13^C NMR, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}; HRESIMS *m*/*z* 249.1235 \[M + H\]^+^ (calcd for C~13~H~17~N~2~O~3~, 249.1234).

### Bohemamine D (**3**): {#sec3.4.3}

colorless oil, \[α\]^23^~D~ −34 (*c* 0.05, MeOH); UV (MeOH) λ~max~ (log ε) 252 (4.05), 283 (3.79), 332 (3.69) nm; ECD (*c* = 0.40 mM, MeOH) λ~max~ (Δε) 336 (−19.0), 297 (+24.5) nm; IR (NaCl disk) ν~max~ 3430, 2100, 1645, 1506, 1394, 1206, 1135, 1058, 793, 733 cm^--1^; ^1^H and ^13^C NMR, [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}; HRESIMS *m*/*z* 251.1391 \[M + H\]^+^ (calcd for C~13~H~19~N~2~O~3~, 251.1390).

### Bohemamine E (**4**): {#sec3.4.4}

colorless oil, \[α\]^23^~D~ −7 (*c* 0.09, MeOH); UV (MeOH) λ~max~ (log ε) 252 (4.01), 280 (3.78), 335 (3.70) nm; ECD (*c* = 0.25 mM, MeOH) λ~max~ (Δε) 335 (+45.8), 282 (−106.8), 248 (+29.9), 207 (−10.5) nm; IR (NaCl disk) ν~max~ 3422, 2092, 1638, 1201, 1130, 734 cm^--1^; ^1^H and ^13^C NMR, [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}; HRESIMS *m*/*z* 281.1496 \[M + H\]^+^ (calcd for C~14~H~21~N~2~O~4~, 281.1496).

### Bohemamine F (**5**): {#sec3.4.5}

colorless oil, \[α\]^23^~D~ +422 (*c* 0.16, MeOH); UV (MeOH) λ~max~ (log ε) 246 (4.02), 288 (3.77), 338 (3.66) nm; ECD (*c* = 0.41 mM, MeOH) λ~max~ (Δε) 339 (+57.6), 290 (−93.7), 248 (+28.7), 207 (−26.2) nm; IR (NaCl disk) ν~max~: 3432, 2101, 1643, 1506, 1361, 1228, 1134, 1099, 756 cm^--1^; ^1^H and ^13^C NMR, [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}; HRESIMS *m*/*z* 247.1441 \[M + H\]^+^ (calcd for C~14~H~19~N~2~O~2~, 247.1441).

### Bohemamine G (**6**): {#sec3.4.6}

colorless oil, \[α\]^23^~D~ +17 (*c* 0.05, MeOH); UV (MeOH) λ~max~ (log ε) 245 (4.09), 284 (3.81), 337 (3.71) nm; ECD (*c* = 0.38 mM, MeOH) λ~max~ (Δε) 335 (+34.9), 284 (−72.3), 244 (+16.8), 209 (−7.1) nm; IR (NaCl disk) ν~max~ 3428, 2100, 1504, 1132, 677 cm^--1^; ^1^H and ^13^C NMR, [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}; HRESIMS *m*/*z* 263.1754 \[M + H\]^+^ (calcd for C~15~H~23~N~2~O~2~, 263.1754).

### Bohemamine H (**7**): {#sec3.4.7}

colorless oil, \[α\]^23^~D~ +37 (*c* 0.03, MeOH); UV (MeOH) λ~max~ (log ε) 244 (4.09), 284 (3.81), 337 (3.71) nm; ECD (*c* = 0.40 mM, MeOH) λ~max~ (Δε) 331 (+63.2), 281 (−129.0), 244 (+25.7), 207 (−8.2) nm; IR (NaCl disk) ν~max~ 3429, 2099, 1638, 1506, 1260, 1174, 1121, 734 cm^--1^; ^1^H and ^13^C NMR, [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}; HRESIMS *m*/*z* 249.1596 \[M + H\]^+^ (calcd for C~14~H~21~N~2~O~2~, 249.1598).

### Bohemamine I (**8**): {#sec3.4.8}

colorless oil, \[α\]^23^~D~ +39 (*c* 0.11, MeOH); UV (MeOH) λ~max~ (log ε) 248 (4.02), 282 (3.78), 336 (3.69) nm; ECD (*c* = 0.37 mM, MeOH) λ~max~ (Δε) 335 (+18.7), 284 (−38.4), 246 (+10.7), 214 (−4.9) nm; IR (NaCl disk) ν~max~ 3431, 2100, 1645, 1506, 1258, 1137, 794, 723, 704 cm^--1^; ^1^H and ^13^C NMR, [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}; HRESIMS *m*/*z* 271.1443 \[M + H\]^+^ (calcd for C~16~H~19~N~2~O~2~, 271.1441).

### NP25302 (**9**): {#sec3.4.9}

\[α\]^23^~D~ +104 (*c* 0.10, MeOH), literature^[@cit6c]^ \[α\]^24^~D~ +116 (*c* 0.11, MeOH); ECD (*c* = 0.40 mM, MeOH) λ~max~ (Δε) 335 (+54.3), 283 (−115.9), 248 (+27.4), 210 (−12.2) nm.

Methylation of **3** {#sec3.5}
--------------------

To a solution of **3** (1.5 mg) in DMF (anhydrous, 0.5 mL) was added 2.0 mg of NaH. After allowing it to stir at 0 °C for 0.5 h, 20 μL of CH~3~I was added into the reaction mixture. It was stirred at room temperature for another 0.5 h. Then, a saturated solution of NH~4~Cl (2.0 mL) was added to quench the reaction. The product was extracted with EtOAc (3 × 3.0 mL) and purified by reversed-phase HPLC (Phenomenex Luna, C~18~, 250 × 10.0 mm, 2.5 mL/min, 5 μm) using a gradient solvent system from 20% to 100% CH~3~CN (0.1% formic acid) over 20 min to afford compound **3a** (0.5 mg, *t*~R~ = 14.4 min). Compound **3a**: white powder; ^1^H NMR (600 MHz, CDCl~3~) δ 5.99 (m, 1H, H-2′), 5.05 (s, 1H, H-2), 3.62 (m, 1H, H-4), 3.29 (s, 3H, 3-NCH~3~), 3.27 (s, 3H, 7-OCH~3~), 2.17 (s, 3H, H-5′), 2.17 (m, 1H, H-5), 2.09 (m, 1H, H-6), 2.00 (m, 1H, H-5), 1.90 (s, 3H, H-4′), 1.88 (m, 1H, H-6), 1.28 (d, *J* = 6.8, 3H, H-8); ^13^C and 2D NMR, [Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acs.jnatprod.5b00604/suppl_file/np5b00604_si_001.pdf); HRESIMS *m*/*z* 279.1704 \[M + H\]^+^ (calcd for C~15~H~23~N~2~O~3~, 279.1703).

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acs.jnatprod.5b00604](http://pubs.acs.org/doi/abs/10.1021/acs.jnatprod.5b00604).^13^C and 2D NMR data of **3a**, calculated ^13^C NMR shifts for compound **1**, computation methods of NMR and ECD, HRESIMS and NMR spectra for compounds **1**--**8** and **3a**, a description of the bioassay protocols used ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acs.jnatprod.5b00604/suppl_file/np5b00604_si_001.pdf))
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